PPARA and metabolic dysfunction-associated steatotic liver disease: Through the CD36-PPAR-CYP4A3 pathway, our work showed that large doses of icariin can greatly reduce lipid buildup in the liver and increase mitochondrial fatty acid oxidation in the liver, further reducing non-alcoholic fatty liver disease.